Suppression of ongoing experimental arthritis by a Chinese herbal formula (Huo-luo-xiao-ling dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation

View/ Open
Author
Yang, Ying-Hua
Rajaiah, Rajesh
Lee, David Y.-W
Fong, Harry H. S.
Lao, Lixing
Berman, Brian M.
Moudgil, Kamal D.
Published Version
https://doi.org/10.1155/2011/642027Metadata
Show full item recordCitation
Yang, Ying-Hua, Rajesh Rajaiah, David Y.-W Lee, Zhongze Ma, Hua Yu, Harry H. S. Fong, Lixing Lao, Brian M. Berman, and Kamal D. Moudgil. 2011. Suppression of ongoing experimental arthritis by a Chinese herbal formula (Huo-luo-xiao-ling dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation. Evidence Based Complementary and Alternative Medicine 2011: 642027.Abstract
Rheumatoid arthritis (RA) is one of the major autoimmune diseases of global prevalence. The use of the anti-inflammatory drugs for the treatment of RA is associated with severe adverse reactions and toxicity. This limitation has necessitated the search for novel therapeutic products. We report here a traditional Chinese medicine-based herbal formula, Huo luo xiao ling dan (HLXL), which has potent antiarthritic activity as validated in the rat adjuvant-induced arthritis (AA) model. HLXL (2.3 g/Kg) was fed to Lewis (RT.1[super]1) rats daily by gavage beginning at the onset of arthritis and then continued through the observation period. HLXL inhibited the severity of ongoing AA. This suppression of arthritis was associated with significant alterations in the T cell proliferative and cytokine responses as well as the antibody response against the disease-related antigen, mycobacterial heat-shock protein 65 (Bhsp65). There was a reduction in the level of the proinflammatory cytokines IL-17 and IL-1β but enhancement of the anti-inflammatory cytokine IL-10 level. In addition, there was inhibition of both the anti-Bhsp65 antibody response and the serum level of nitric oxide. Thus, HLXL is a promising CAM modality for further testing in RA patients.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958519/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:4874817
Collections
- HMS Scholarly Articles [17298]
Contact administrator regarding this item (to report mistakes or request changes)